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a  b  s  t  r  a  c  t
A  68-year-old  female,  suffering  from  rheumatoid  arthritis,  was  admitted  to our  institution  for  right heart
failure  with  massive  pericardial  effusion.  Her pericardial  effusion  had  increased  after  starting  inﬂiximab,
tumor  necrosis  factor (TNF)-inhibitor  therapy,  despite  improvement  in  arthralgia.  Hemodynamic  ﬁndings
demonstrated  effusive–constrictive  pericarditis.  Because  association  between  exacerbation  of pericardi-
tis and  inﬂiximab  was  highly  suspected  through  her  clinical  course,  its  administration  was  stopped.  We
should pay  much  attention  to  pericardial  effusion  and  symptoms  of  right  heart  failure  after  startingnﬂiximab
ericardial effusion
heumatoid arthritis
NF-inhibitor therapy
TNF-inhibitor  therapy  in  patients  with  rheumatoid  arthritis.
<Learning  objective:  TNF-inhibitor  therapy  has  become  a treatment  option  for rheumatoid  arthritis,
however,  it  may  cause  exacerbation  of extra  articular  manifestations  such  as pericarditis.  We  encoun-
tered a patient  with  rheumatoid  arthritis  who  developed  effusive-constrictive  pericarditis  while  on
TNF-inhibitor  therapy.  We  should  pay  much  attention  to  pericardial  effusion  and  symptoms  of  right
g  TNF
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Pericarditis is the most common cardiac involvement in
heumatoid arthritis (RA) [1],  but effusive–constrictive pericarditis
s rare [2].  Although tumor necrosis factor (TNF)-inhibitor ther-
py has improved the management of RA [3],  its effects on extra
rticular manifestations such as pericarditis remains unclear. We
escribe a patient with RA who developed effusive–constrictive
ericarditis while on TNF-inhibitor therapy.
ase report
A 68-year-old female was admitted to our department for
urther examinations and treatment for right heart failure with
assive pericardial effusion.
At 62 years, she was diagnosed with RA. Various anti-rheumatic
rugs including prednisolone, salazosulfapyridine, tacrolimus,
nd methotrexate were administered, but ineffective. Moderate
mount of pericardial effusion was noted, but was being controlled
ith diuretics.
At 68 years, she was referred to our hospital for treatment ofA. Inﬂiximab, TNF-inhibitor therapy, was started, and her arthral-
ia improved. Rheumatoid factor (RF) improved from 890.3 to
94.2 IU/ml. However, leg edema and anorexia were exacerbated
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after the second dose of inﬂiximab (total dose 200 mg), 40 days
after starting inﬂiximab. Chest X-rays showed that cardiothoracic
ratio was 65% before treatment with inﬂiximab and 70% 40 days
after starting inﬂiximab. Echocardiograms showed that pericar-
dial effusion increased compared with that before treatment with
inﬂiximab, and it contained ﬁbrin-like echo (Fig. 1).
On physical examination, blood pressure was  110/80 mmHg,
and pulse rate was  90 beats per minute. Jugular venous dilata-
tion with Kussmaul sign was noted. Pericardial knock sound was
not heard. Pitting edema was noted in lower extremities. Labo-
ratory data on admission showed 3.1 mg/dl of C reactive protein,
4100/l  of white blood cell, 367.3 IU/ml of RF, 6.6 g/dl of total pro-
tein, 333 IU/l of lactate dehydrogenase (LDH), 117 mg/dl of glucose,
and 116 pg/ml of brain natriuretic peptide.
Right-sided cardiac catheterization and pericardiocentesis were
performed. Mean right atrial pressure was  24 mmHg with promi-
nent x descent and the cardiac index was  1.6 L/min/m2. Mean
right atrial pressure decreased to 17 mmHg  with prominent y
descent and cardiac index increased to 2.6 L/min/m2 after 540 mL
of ﬂuid was  drained. Dip and plateau conﬁguration of the diastolic
right ventricular pressure was also shown after pericardiocen-
tesis (Fig. 2). These ﬁndings suggested the hemodynamics of
effusive–constrictive pericarditis.
Chest computed tomography before pericardiocentesis showed
massive pericardial effusion and thickening of both pericardium
and epicardium (Fig. 3). After pericardiocentesis, pericardial effu-
sion markedly decreased, but thickening of pericardium and
epicardium remained (Fig. 3).
vier Ltd. All rights reserved.
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sig. 1. Transthoracic echocardiograms. After treatment with inﬂiximab (B), perica
nterval between these two  echocardiograms was two  months.
Pericardial ﬂuid was bloody. Laboratory data of the ﬂuid showed
0 mg/dl of glucose, 6.6 g/dl of total protein, 9120 IU/l of LDH,
21.6 IU/ml of RF, and 60 U/l of adenosine deaminase (ADA). Neu-
rophilia was detected (48% neutrophils and 8% lymphocytes).
oth microbial and cytological examinations of the ﬂuid were
egative. Acid-fast bacillus smear and polymerase chain reac-
ion for mycobacterial DNA were also negative. Based upon these
ata, the most probable cause of pericardial effusion was  RA.
owever, pericardial effusion increased after starting inﬂiximab
espite improvement in arthritis. Considering the possibility of
n adverse effect of inﬂiximab on rheumatic pericarditis, its
dministration was stopped. Symptoms markedly improved after
ig. 2. Right heart catheterization data. Before pericardiocentesis (A), mean right atrial pres
ressure (RVP) was  also elevated. After pericardiocentesis (B), mean RAP decreased to 1
hown.ffusion increased compared with that before treatment with inﬂiximab (A). Time
pericardiocentesis and pericardial effusion has not increased after
discontinuing inﬂiximab.
Discussion
We present a case of effusive–constrictive pericarditis, show-
ing exacerbation during treatment for RA. Management of such a
patient should be determined considering the hemodynamics and
causes of the pericarditis.
In this case, hemodynamic ﬁndings before pericardiocentesis
were compatible with cardiac tamponade, which characteristi-
cally shows elevated right atrial pressure with prominent x but
sure (RAP) was elevated (24 mmHg) with prominent x descent, and right ventricular
7 mmHg  with prominent y descent and dip and plateau conﬁguration of RVP was
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[ig. 3. Chest computed tomography. Before pericardiocentesis (A), massive peric
ericardium and epicardium remained after pericardiocentesis (B).
lunted y descent. Findings after pericardiocentesis showed ele-
ation and equalization of diastolic pressures, prominent y, and
ight ventricular dip and plateau, which was compatible with
onstrictive pericarditis. The evolution from tamponade to con-
triction following the removal of pericardial ﬂuid is characteristic
f effusive–constrictive pericarditis [4].
While pericarditis is the most common cardiac involvement in
A, effusive–constrictive pericarditis is rare. Tuberculosis is one
f the main causes of effusive–constrictive pericarditis. Exclusion
f tuberculosis is important because she may  need additional
mmunosuppressants for RA-associated pericarditis, which can
ake infections worse [5].  In our case, pericardial ﬂuid was not
onsidered to have been caused by tuberculosis because it showed
eutrophilia, but not lymphocytosis and results of mycobacterial
xaminations were negative, although slightly elevated ADA
as detected. Since neutrophilia and high RF were detected,
e considered that her effusive–constrictive pericarditis was
ssociated with RA. In this case, pericardial effusion was bloody.
requency of bloody pericardial effusion among RA-associated
ericarditis is difﬁcult to clarify, because pericardiocentesis is
erformed in a very limited number of patients with RA-associated
ericarditis. In patients with refractory RA-associated pericarditis
ho need pericardiocentesis, bloody pericardial effusion is not so
are [6].  Bloody pericardial effusion may  be likely to develop into
ffusive–constrictive pericarditis.
Another important point is that pericardial effusion increased
fter treatment with inﬂiximab. There are several case reports
7–13] that TNF-inhibitor therapy for RA may  cause exacerba-
ion of pericardial effusion by several possible mechanisms such
s infective pericarditis, cutaneous vasculitis, drug-induced lupus,
aradoxical ﬂare, and drug side effects. In addition, it was reported
hat pericarditis may  develop in patients with Crohn’s disease
s a complication of inﬂiximab therapy [14]. On the other hand,
nﬂiximab therapy was reported to be effective in patients with
heumatoid vasculitis, who  suffered from massive pericardial effu-
ion and heart failure [15]. The effect of inﬂiximab on pericarditis
ssociated with RA is still controversial. In our case, the associa-
ion between exacerbation of pericarditis and inﬂiximab is highly
uspected through her clinical course. We  decided to control her
[
[effusion with thickened pericardium and epicardium were shown. Thickening of
pericarditis by stopping the administration of inﬂiximab, which
was successful.
In conclusion, we encountered a patient with
effusive–constrictive pericarditis being treated for RA with
inﬂiximab. We  should pay much attention to pericardial effusion
and symptoms of right heart failure after starting TNF-inhibitor
therapy in patients with RA.
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